Copyright ©The Author(s) 2015.
World J Hepatol. May 8, 2015; 7(7): 980-992
Published online May 8, 2015. doi: 10.4254/wjh.v7.i7.980
Table 2 Information of clinical trials of tumor vaccine on hepatocellular carcinoma after 2008
InterventionsDesignStart yearMain inclusion criteriaPrimary outcomesRegistered No.Status
AFP + GM-CSF plasmid prime and AFP adenoviral vector boostPhase I/II2008Locoregionally treated HCCDose, toxicity, and immunological response rateNCT00669136Terminated because of poor accrual
DC loaded with autologous tumorPhase II2008Metastatic HCC, available of tumor tissue2-mo response rateNCT00610389Unknown
DC loaded with specific peptides of AFPPhase I/II2009Patients with previous treatment, AFP ≥ 40 ng/mL, HLA A 0201 groupAdverse eventsNCT01128803Terminated
DEC-205-NY-ESO-1 fusion protein vaccinePhase I2012After resection and TACE for HCCAdverse eventsNCT01522820Recruiting
COMBIG-DC: allogeneic DC cancer vaccinePhase I2013Not eligible for curative treatment or TACE, BCLC stage B and CAdverse eventsNCT01974661Recruiting
In-situ therapeutic cancer vaccinePhase I2013Refractory HCC, not eligible for or failed any treatment, AFP > 30SafetyNCT01923233Recruiting
V5 therapeutic vaccinePhase III2014Advanced HCCChanges in plasma AFPNCT02232490Not yet recruiting